Top Markets
Coin of the day
Gongwin Biopharm Holdings Co., Ltd. Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

6617
Rank in Stocks #13748
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical... Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Share Price
$3.83
Market Cap
$464.45M
Change (1 day)
-1.63%
Change (1 year)
17.17%
Country
TW
Trade Gongwin Biopharm Holdings Co., Ltd. (6617)

Category

P/S ratio for Gongwin Biopharm Holdings Co., Ltd. (6617)
P/S ratio as of 2026 TTM: 0
According to Gongwin Biopharm Holdings Co., Ltd. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Gongwin Biopharm Holdings Co., Ltd. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
0.25 -
US
- -
US
0.22 -
US
- -
US
7.03 -
AU